Mohit Bansal
Stock Analyst at Wells Fargo
(1.52)
# 1637
Out of 5,370 analysts
181
Total ratings
53.33%
Success rate
5.41%
Average return
Main Sectors:
| Name | Action | PT | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
REGN Regeneron Pharmaceut... | Downgrades: Equal-Weight | 700 580 | 522.29 | 11.05% | 18 | May 30, 2025 | |
XENE Xenon Pharmaceutical... | Maintains: Overweight | 50 47 | 32.07 | 46.55% | 2 | May 13, 2025 | |
HALO Halozyme Therapeutic... | Maintains: Equal-Weight | 60 65 | 53.85 | 20.71% | 7 | May 7, 2025 | |
BMY Bristol-Myers Squibb | Maintains: Equal-Weight | 62 53 | 48.55 | 9.17% | 9 | Apr 28, 2025 | |
IRWD Ironwood Pharmaceuti... | Downgrades: Equal-Weight | 7 1 | 0.68 | 47.06% | 4 | Apr 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 970 1100 | 807.13 | 36.29% | 17 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 120 140 | 110.72 | 26.45% | 11 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 210 240 | 190.7 | 25.85% | 8 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 165 140 | 131.07 | 6.81% | 13 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Overweight | 130 170 | 109.64 | 55.05% | 2 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Equal-Weight | 460 460 | 450.66 | 2.07% | 10 | Jan 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 335 280 | 295.12 | -5.12% | 9 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 30 | 19.97 | 50.23% | 1 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 170 | 106.15 | 60.15% | 1 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 70 | 21.85 | 220.37% | 1 | Nov 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 125 110 | 80.88 | 36% | 10 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Overweight | 9 27 | 14.73 | 83.3% | 4 | Oct 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 115 90 | 56.19 | 60.17% | 5 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 28 30 | 24.39 | 23% | 10 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Overweight | 140 170 | 125.3 | 35.67% | 7 | Apr 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Equal-Weight | 30 40 | n/a | n/a | 1 | Aug 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Overweight | 30 | n/a | n/a | 3 | May 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 27 | 13.46 | 100.59% | 1 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 60 | n/a | n/a | 1 | Jun 4, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 1875 | 12.64 | 14733.86% | 1 | Mar 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 35 | n/a | n/a | 1 | Feb 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 25 30 | 29.61 | 1.32% | 4 | Jan 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 175 | n/a | n/a | 1 | Dec 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 36 | 0.99 | 3536.36% | 1 | Nov 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 125 225 | n/a | n/a | 4 | Oct 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 16 19 | 13.43 | 41.47% | 3 | Apr 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 8 5 | n/a | n/a | 3 | Apr 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 160 140 | n/a | n/a | 2 | Mar 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Neutral | 30 60 | 1.08 | 5455.56% | 4 | Dec 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 100 116 | n/a | n/a | 2 | Oct 2, 2017 |